



Citra-Lock™

**Sécurité &
Efficacité**

**Solution
verrou**

Seringue préremplie



Citra-Lock™ S

**Anti biofilm
Anti infectieux
Anti coagulant**

4% trisodium citrate



Dirinco®


Always innovating



La Plus Sûre solution verrou pour les cathéters centraux

Citra-Lock est recommandé par le Guide Européen des Bonnes Pratiques Rénales (European Renal Best Practice - ERBP) et par la Société Américaine de Néphrologie (American Society of Diagnostic and Interventional Nephrology).

Les solutions verrou au citrate ont fait l'objet de nombreuses études¹. Citralock™ 4% offre le meilleur ratio bénéfices/risques.



Avantages cliniques du Citra-Lock™ 4% (par rapport à l'héparine):

- Sécurité
- Élimination des saignements liés à l'utilisation d'héparine
- Amélioration de la fiabilité des tests INR (temps de prothrombine - temps / rapport international normalisé)
- Sans danger pour la thrombopénie induite par l'héparine (TIH de patients)
- Pas d'effet secondaire

RÉFÉRENCES :

1. **Superior antimicrobial activity of trisodium citrate over heparin for catheter locking**, Marcel C. Weijmer, Yvette J. Debets-Ossenkopp, Francien J. van de Vondervoort and Piet M. ter Wee, Department of Nephrology and Department of Medical Microbiology and Infection Control, Vrije Universiteit Medical Center, Amsterdam, The Netherlands, *Nephrol Dial Transplant* (2002) 17: 2189-2195
2. **Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygelatine: a prospective randomized study**, Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P
3. **Risk of heparin lock-related bleeding when using indwelling venous catheters in haemodialysis**, Hüseyin Karaaslan, Pierre Peyronnet, Daniel Benevent, Christian Lagarde, Michel Rince, Claude Leroux-Robert, Service de Néphrologie CHU Dupuytren, Limoges, France, *Nephrol Dial Transplant*, (2001) 16: 2072-2074
4. **A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters**, Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y, Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium, *Int J Artif Organs* 2001 Apr;24(4):208-11
5. **Concentrated Sodium Citrate (23%) for Catheter Lock**, Stephen R. Ash, Rita A. Mankus, James M. Sutton, Ruth E. Criswell, Carol C. Crull, Katherine A. Velasquez, Brian D. Smeltzer, Todd S. Ing, Greater Lafayette Healthcare Services, Inc. (previously St. Elizabeth Medical Center and Lafayette Home Hospital); Arnett Clinic, Lafayette; HemoCleanse, Inc. and Ash Medical Systems, Inc., West Lafayette, Indiana; University of Illinois, Chicago, Illinois, U.S.A. *Hemodial Int* 2000;4: 22-31
6. **Sodium citrate 4% locking solution in hemodialysis patients with central venous catheters**, Calantha K. Yon and Chai L. Low, *Am J Health-Syst Pharm.* 2013; 70:131-6
7. **Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP)**, Raymond Vanholder¹, Bernard Canaud², Richard Fluck³, Michel Jadoul⁴, Laura Labriola⁵, A. Marti-Monros⁶, J. Tordoir⁶ and W. Van Biesen¹
¹Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium, ²Nephrology, Dialysis and Intensive Care Unit, Lapeyronie University Hospital, Montpellier, France, ³Department of Renal Medicine, Royal Derby Hospital, Derby, UK, ⁴Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁵Nephrology Department, Consorcio Hospital General Universitario, Valencia, Spain and ⁶Vascular Surgery, Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands *NDT Plus* (2010) 3: 234-246 doi: 10.1093/ndtplus/sfq041
8. **Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters**, Jones SM, Ravani P, Hemmelgarn BR, Muruve D, Macrae JM. Division of Nephrology, University of Calgary, Calgary, Alberta, Canada. *Am J Kidney Dis.* 2011 Mar;57(3):449-55. Epub 2011 Jan 22.
9. **Sodium citrate 4% locking solution for central venous dialysis catheters—an effective, more cost-efficient alternative to heparin**, Linda Grudzinski¹, Patricia Quinan¹, Sophie Kwok¹ and Andreas Pierratos^{1,2} Department of Nephrology, Humber River Regional Hospital and ²Department of Medicine, University of Toronto, Toronto, Ontario, Canada, *Nephrol Dial Transplant* (2007) 22: 471-476
10. **Trisodium citrate 4%—an alternative to heparin capping of haemodialysis catheters**, Charmaine E. Lok, Debra Appleton, Cynthia Bhola, Brian Khoo and Robert M. A. Richardson, Department of Medicine, Division of Nephrology, The Toronto General Hospital, *Nephrol Dial Transplant.* (2007) 22 (2): 477-483.
11. **Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces**, Robert M. Q. Shanks¹, Jennifer L. Sargent¹, Raquel M. Martinez¹, Martha L. Graber² and George A. O'Toole¹ ¹Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, NH 03755 and ²Department of Medicine, Section of Hypertension and Nephrology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03766, USA. *Nephrol Dial Transplant* (2006) 1 of 9 doi:10.1093/ndt/gfl170

La **Plus Effective** solution verrou pour les cathéters centraux



Citra-Lock™ 4% est efficace pour éviter la thrombose du cathéter

Le Citra-Lock™ 4% (TSC) agit comme un anti-coagulant sans incidence accrue d'infection.

Utilisation comparée Citrate 4% / Héparine sur des patients dialysés par cathéter central veineux

Yon et al, Am J Health-Syst Pharm. 2013; 70:131-6

Résultats	Héparine (n=60)	Sodium Citrate (n=60)	p
No. CRIs ^a	20	11	0.026
No. CRIs/1000 catheter-days	1.90	0.81	0.026
Organisms isolated from CRIs			
Enterobacter species	5	0.55	
MSSA	5	2	0.25
Other gram-positive species	4	2	0.42
Other gram-negative species	4	2	0.42
Pseudomonas aeruginosa	3	0	0.087
No. hospitalizations related to CRIs	16	9	0.064
No. thrombosis episodes	41	40	0.24
No. alteplase administrations	41	40	0.24
No. catheters exchanged or removed	34	18	0.002
No. catheters exchanged/1000 catheter-days	3.24	1.33	0.002



Avantages cliniques du **Citra-Lock™ 4%** (par rapport à l'héparine):

- Réduction de la coagulation et de l'utilisation de thrombolytiques tPA
- Réduction du nombre de remplacement de cathéter
- Réduction du biofilm
- Réduction du temps d'hospitalisation
- Réduction du coût



**Anti biofilm
Anti infectieux
Anti coagulant**

4% trisodium citrate



Citra-Lock™

Améliorer la sécurité & Simplifier l'utilisation

Sécurité & Efficacité

Solution verrou

www.citra-lock.com pour regarder les instructions d'utilisation en vidéo



Citra-Lock™ 4%
Ampoule 5ml



La boîte contient
20 ampoules de 5 ml

Art.nr. Citra-Lock™ 4%: 24060201

CE 1275



Citra-LockTMS 4%
Seringue de 2,5 ml

La boîte contient
120 seringues de 2,5 ml

Art.nr. Citra-LockTMS 4% seringue préremplie: 24060200

CE 0344

Disponible également dans les concentrations suivantes: Citra-Lock™ 30%
Citra-Lock™ 46,7%

Citra-Lock™ est un produit Dirinco enregistré comme dispositif médical

Distributeur de Citra-Lock™

HEMOLAB

Dirinco®
Always innovating

Dirinco BV • Oss • The Netherlands

www.citra-lock.com
info@citra-lock.com

CL4% FR V1 / 06-13